Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$12.46 - $29.95 $9.8 Million - $23.5 Million
786,200 Added 5697.1%
800,000 $23.7 Million
Q3 2023

Nov 14, 2023

SELL
$14.09 - $19.87 $1.12 Million - $1.58 Million
-79,500 Reduced 85.21%
13,800 $219,000
Q2 2023

Aug 14, 2023

BUY
$3.75 - $20.05 $349,875 - $1.87 Million
93,300 New
93,300 $1.76 Million
Q4 2020

Feb 16, 2021

BUY
$3.7 - $7.66 $185,000 - $383,000
50,000 Added 33.33%
200,000 $1.29 Million
Q1 2019

May 14, 2019

BUY
$2.41 - $5.91 $301,250 - $738,750
125,000 Added 500.0%
150,000 $405,000
Q4 2018

Jan 30, 2019

BUY
$3.94 - $9.7 $98,500 - $242,499
25,000 New
25,000 $121,000
Q2 2018

Aug 14, 2018

SELL
$9.52 - $12.15 $428,400 - $546,750
-45,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$6.7 - $12.95 $301,500 - $582,750
45,000 New
45,000 $474,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.